1. Name and Address of Reporting Person
Versant Venture Capital VII, L.P.
*(Last) (First) (Middle)*
ONE SANSOME STREET, SUITE 3630
(Street) SAN FRANCISCO CA 94104
(City) (State) (Zip)

2. Date of Event Requiring Statement
10/05/2020

3. Issuer Name and Ticker or Trading Symbol
ADURO BIOTECH, INC. [ KDNY ]

4. Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below)
Other (specify below)

5. If Amendment, Date of Original Filed

6. Individual or Joint/Group Filing
Form filed by One Reporting Person X
Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 4)</th>
<th>2. Amount of Securities Beneficially Owned (Instr. 4)</th>
<th>3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)</th>
<th>4. Nature of Indirect Beneficial Ownership (Instr. 5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>4,733,023(1)</td>
<td>I</td>
<td>See footnote(2)</td>
</tr>
<tr>
<td>Common Stock</td>
<td>722,247(1)</td>
<td>I</td>
<td>See footnote(3)</td>
</tr>
<tr>
<td>Common Stock</td>
<td>2,433,099(1)</td>
<td>I</td>
<td>See footnote(4)</td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 4)</th>
<th>2. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)</th>
<th>4. Conversion or Exercise Price of Derivative Security</th>
<th>5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)</th>
<th>6. Nature of Indirect Beneficial Ownership (Instr. 5)</th>
</tr>
</thead>
</table>

1. Name and Address of Reporting Person
Versant Venture Capital VII, L.P.
*(Last) (First) (Middle)*
ONE SANSOME STREET, SUITE 3630
(Street) SAN FRANCISCO CA 94104
(City) (State) (Zip)

1. Name and Address of Reporting Person
Versant Voyageurs I Parallel, L.P.
*(Last) (First) (Middle)*
ONE SANSOME STREET, SUITE 3630
(Street) SAN FRANCISCO CA 94104
(City) (State) (Zip)
FRANCISCO

(City) (State) (Zip)

1. Name and Address of Reporting Person

Versant Voyageurs I, L.P.

(Last) (First) (Middle)

ONE SANSOME STREET, SUITE 3630

(Street)

SAN FRANCISCO CA 94104

(City) (State) (Zip)

Explanation of Responses:

1. The shares reported represent the number of shares of Issuer common stock received by the Reporting Person on the Effective Date in connection with the merger of Chinook Therapeutics U.S., Inc. ("Private Chinook") into the Issuer.

2. These securities are held of record by Versant Venture Capital VII, L.P. ("Versant VII"). Versant Ventures VII GP, L.P. ("Versant Ventures VII GP") is the general partner of Versant VII, and Versant Ventures VII GP-GP, LLC ("Versant Ventures VII GP-GP") is the general partner of Versant Ventures VII GP. Jerel Davis is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VII; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Jerel Davis is a director of the Issuer and, accordingly, files separate Section 16 reports.

3. These securities are held of record by Versant Voyageurs I Parallel L.P. ("Versant I Parallel"). Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP") is the general partner of Versant I Parallel. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant Voyageurs I GP. Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Jerel Davis is a managing director of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Jerel Davis is a director of the Issuer and, accordingly, files separate Section 16 reports.

4. These securities are held of record by Versant Voyageurs I, L.P. ("Versant Voyageurs I"). Versant Voyageurs I GP Company is the general partner of Versant Voyageurs I. Jerel Davis is a director of Versant Voyageurs I GP Company and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Jerel Davis is a director of the Issuer and, accordingly, files separate Section 16 reports.

Remarks:

/s/ Versant Venture Capital VII, L.P.; Versant Voyageurs I, L.P., Versant Voyageurs I Parallel, L.P.,
By: Robin L. Praeger,
President or Managing Director

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.